An immunotherapy targeting IL-7R in preclinical stage to treat solid tumors

OSE-703 (Effi-3) is a humanized monoclonal antibody directed against the extracellular domain of the alpha-chain of the receptor for interleukin-7 (CD127), cytotoxic for human cells expressing CD127.

In June 2017, OSE Immunotherapeutics has entered into a multi-year strategic research collaboration on OSE-703 with Memorial Sloan Kettering Cancer Center (MSK) in New York.


The goal of this research collaboration is to explore IL-7R directed immunotherapy OSE-703 for solid tumors with non-small cell lung cancer (NSCLC) as the primary cancer model.

From a large cohort of NSCLCs*, it has been shown that IL-7R was overexpressed in this type of cancer and associated with poor prognosis.

The research program will be conducted by physician-scientist Prasad S. Adusumilli, MD, FACS, a thoracic surgeon with expertise in tumor immunology and a focus on the development of chimeric antigen receptor T-cell (CAR T-cell) immunotherapy.

* Suzuki et al, J Clin Oncol. 2013 Feb 1; 31(4): 490–498.